- Home
- IPHA vs FNGR Comparison
IPHA vs FNGR Comparison
Compare IPHA & FNGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- FNGR
- Stock Information
- Founded
- IPHA 1999
- FNGR 2016
- Country
- IPHA France
- FNGR Singapore
- Employees
- IPHA N/A
- FNGR N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- FNGR Computer Software: Prepackaged Software
- Sector
- IPHA Health Care
- FNGR Technology
- Exchange
- IPHA Nasdaq
- FNGR Nasdaq
- Market Cap
- IPHA 171.6M
- FNGR 108.1M
- IPO Year
- IPHA 2019
- FNGR N/A
- Fundamental
- Price
- IPHA $2.25
- FNGR $2.20
- Analyst Decision
- IPHA Strong Buy
- FNGR
- Analyst Count
- IPHA 1
- FNGR 0
- Target Price
- IPHA $11.50
- FNGR N/A
- AVG Volume (30 Days)
- IPHA 6.4K
- FNGR 304.1K
- Earning Date
- IPHA 09-12-2024
- FNGR 10-14-2024
- Dividend Yield
- IPHA N/A
- FNGR N/A
- EPS Growth
- IPHA N/A
- FNGR N/A
- EPS
- IPHA N/A
- FNGR N/A
- Revenue
- IPHA $36,202,722.00
- FNGR $31,996,577.00
- Revenue This Year
- IPHA N/A
- FNGR $260.03
- Revenue Next Year
- IPHA $105.84
- FNGR N/A
- P/E Ratio
- IPHA N/A
- FNGR N/A
- Revenue Growth
- IPHA N/A
- FNGR N/A
- 52 Week Low
- IPHA $1.81
- FNGR $1.63
- 52 Week High
- IPHA $3.15
- FNGR $7.37
- Technical
- Relative Strength Index (RSI)
- IPHA 49.51
- FNGR 56.53
- Support Level
- IPHA $2.22
- FNGR $2.21
- Resistance Level
- IPHA $2.29
- FNGR $2.42
- Average True Range (ATR)
- IPHA 0.13
- FNGR 0.13
- MACD
- IPHA -0.01
- FNGR 0.02
- Stochastic Oscillator
- IPHA 48.09
- FNGR 67.44
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.